Fresenius Kabi Usa, Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Fresenius Kabi Usa, Llc Pharmaceutical Import Records from India — 6 Products, $71.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Usa, Llc — Pharmaceutical Importer Profile (2026) | 6 Products, $71.2M Trade | TransData Nexus

Fresenius Kabi Usa, Llc

Pharmaceutical Importer · United States · Cardiovascular Focus · $71.2M Total Trade · DGFT Verified

Fresenius Kabi Usa, Llc is a pharmaceutical importer based in United States with a total trade value of $71.2M across 6 products in 5 therapeutic categories. Based on 1,424 verified import shipments from Indian Customs (DGFT) records, Fresenius Kabi Usa, Llc is the #1 buyer in 3 products including Enoxaparin, Heparin, Syringe. Fresenius Kabi Usa, Llc sources from 4 verified Indian suppliers, with Gland Pharma Limited accounting for 91.8% of imports.

Fresenius Kabi Usa, Llc — Import Portfolio & Supplier Network

Fresenius Kabi Usa, Llc import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi Usa, Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$28.6M	738	91.8%
Caplin Steriles Limited	$2.1M	46	6.8%
Immacule Lifesciences Private Limited	$429.0K	11

What Formulations Does Fresenius Kabi Usa, Llc Import?

Formulation	Value	Ships
Low molecular weight heparin enoxaparinsodium injection USP, 40MG in 0.4ML prefilled	$6.3M	137
Low molecular weight heparin	$2.2M	44
(low molecular weight heparin) enoxaparin sodium injection USP, 40MG in 0.4ML pre-filled	$1.7M	43
(low molecular weight heparin) enoxaparin sodium injection USP, 40MG	$1.3M	28
Low molecular weight heparin enoxaparinsodium injection USP, 30MG in 0.3ML prefilled	$982.8K	23
Pharmaceutical formulations	$850.0K	17
Low molecular weight heparin enoxaparinsodium injection USP, 40MG in 0.4ML prefilled	$777.4K	18
(low molecular weightheparin) enoxaparinsodium injection USP,40MG in 0.4ML	$700.0K	14
(low molecular weightheparin) enoxaparinsodium injection USP,40MG	$600.0K	12
Acetylcysteine solution USP 200MG/ML	$588.4K	19
Acetylcysteine solution USP 200MG/ML (20%), 4ML	$466.5K	13
Micafungin for injection 100MG/vial, 10ML	$450.0K	9
Low molecular weightheparin enoxaparinsodium injection USP,30MG in 0.3ML prefilled	$450.0K	9
Low molecular weight heparin enoxaparinsodium injection USP, 60MG in 0.6ML prefilled	$447.7K	10
Low molecular weight enoxaparin sodium injection USP 40MG/0.4ML	$428.9K	9

Fresenius Kabi Usa, Llc imports 166 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Enoxaparin	Cardiovascular	$25.1M	501	9.8%	1
2	Heparin	Cardiovascular	$23.8M	475	5.5%	1
3	Syringe	Medical Devices & Diagnostics	$20.6M	411	9.5%	1
4	Sodium	Nutritional Supplements	$1.2M	24	0.3%	17
5	Acyclovir	Antivirals	$400.0K	8	0.3%	17
6	Voriconazole	Advanced Antifungals	$250.0K	5	0.8%	6

Fresenius Kabi Usa, Llc imports 6 pharmaceutical products across 5 categories into United States totaling $71.2M. The company is the #1 buyer for 3 products: Enoxaparin, Heparin, Syringe.

Fresenius Kabi Usa, Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi USA, LLC is a subsidiary of Fresenius Kabi AG, a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Established in 1999, Fresenius Kabi USA focuses on providing products and services to critically and chronically ill patients, including injectable drugs, advanced transfusion medicine, cell therapy, infusion, and clinical nutrition technologies.

Headquartered at Three Corporate Drive, Lake Zurich, Illinois 60047, Fresenius Kabi USA operates manufacturing and distribution units across the United States, including facilities in Illinois, New York, Pennsylvania, Puerto Rico, the Dominican Republic, Mississippi, and California. The company serves hospitals, long-term care facilities, alternate care sites, and clinics, playing a significant role in the U.S. pharmaceutical distribution network by supplying a wide range of essential medications and medical devices.

2Distribution Network

Fresenius Kabi USA's distribution network is extensive, with manufacturing and distribution facilities strategically located across the United States. These facilities are situated in Illinois, New York, Pennsylvania, Puerto Rico, the Dominican Republic, Mississippi, and California, enabling the company to efficiently serve a broad geographic area. The company's logistics capabilities are robust, ensuring timely delivery of products to hospitals, long-term care facilities, alternate care sites, and clinics nationwide.

3Industry Role

In the United States pharmaceutical supply chain, Fresenius Kabi USA, LLC functions primarily as a pharmaceutical importer and distributor. The company imports a diverse range of pharmaceutical products and medical devices, including injectable drugs, advanced transfusion medicine, cell therapy, infusion, and clinical nutrition technologies. By supplying these products to various healthcare facilities, Fresenius Kabi USA plays a crucial role in ensuring the availability of essential medications and medical devices for critically and chronically ill patients across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi Usa, Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi USA's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from India. The company's total import value from India amounts to $71.2 million USD, encompassing 1,424 shipments and 166 unique formulations across five therapeutic categories. The top five imported products—Enoxaparin, Heparin, Syringe, Sodium, and Acyclovir—account for 99.6% of the total import value, indicating a focused product portfolio.

This concentrated sourcing approach suggests a strategic choice to leverage India's manufacturing capabilities, particularly in the production of generic pharmaceuticals and medical devices. The stability of this relationship is evidenced by the consistent volume of imports over the years, reflecting a reliable supply chain. However, such concentration also poses potential risks, including exposure to supply disruptions or regulatory changes in India.

2Supply Chain Resilience

Fresenius Kabi USA's supply chain resilience is closely tied to its sourcing from India, particularly from suppliers like Gland Pharma Limited, which accounts for 91.8% of the total import value. This heavy reliance on a single supplier could pose risks in the event of production issues, regulatory changes, or geopolitical tensions affecting India. The company's import data indicates a diverse range of formulations, with 166 unique products, suggesting efforts to mitigate risks by not relying solely on a single product line.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and monitoring of pharmaceutical products. The FDA enforces several key pieces of legislation, including the Federal Food, Drug, and Cosmetic Act (FDCA), which sets forth the standards for drug safety, efficacy, and quality. Additionally, the Drug Enforcement Administration (DEA) regulates controlled substances, ensuring compliance with the Controlled Substances Act.

For Indian pharmaceutical companies aiming to export to the U.S., obtaining FDA approval is mandatory. This process involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generics, providing comprehensive data on the drug's safety, efficacy, and manufacturing processes. The FDA evaluates these submissions to ensure that imported drugs meet U.S. standards before they can be marketed domestically.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Indian exporters must ensure that their manufacturing facilities are registered with the FDA and that their products are listed in the FDA's Drug Registration and Listing System. Additionally, compliance with Good Manufacturing Practice (GMP) standards is essential. The FDA recognizes GMP certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), provided they meet the FDA's criteria.

Fresenius Kabi Usa, Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi USA's product strategy focuses on critical care therapies, with a significant emphasis on cardiovascular medications, medical devices, and diagnostics. The company's top three imported product categories—Cardiovascular (68.5%), Medical Devices & Diagnostics (28.9%), and Nutritional Supplements (1.7%)—reflect this focus. The high import values of Enoxaparin ($25.1M) and Heparin ($23.8M) indicate a strong commitment to providing essential anticoagulant therapies.

The market demand for these products is driven by the prevalence of cardiovascular diseases and the need for effective anticoagulation therapies in critical care settings. The substantial importation of medical devices and diagnostics underscores the importance of advanced technologies in patient monitoring and treatment. By focusing on these therapeutic areas, Fresenius Kabi USA aims to address critical healthcare needs and enhance patient outcomes.

2Sourcing Profile

Fresenius Kabi USA's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, particularly from suppliers like Gland Pharma Limited, which accounts

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Fresenius Kabi Usa, Llc

What products does Fresenius Kabi Usa, Llc import from India?

Fresenius Kabi Usa, Llc imports 6 pharmaceutical products across 5 categories. Top imports: Enoxaparin ($25.1M), Heparin ($23.8M), Syringe ($20.6M), Sodium ($1.2M), Acyclovir ($400.0K).

Who supplies pharmaceuticals to Fresenius Kabi Usa, Llc from India?

Fresenius Kabi Usa, Llc sources from 4 verified Indian suppliers. The primary supplier is Gland Pharma Limited (91.8% of imports, $28.6M).

What is Fresenius Kabi Usa, Llc's total pharmaceutical import value?

Fresenius Kabi Usa, Llc's total pharmaceutical import value from India is $71.2M, based on 1,424 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi Usa, Llc focus on?

Fresenius Kabi Usa, Llc imports across 5 categories. The largest: Cardiovascular (68.5%), Medical Devices & Diagnostics (28.9%), Nutritional Supplements (1.7%).

Get Full Fresenius Kabi Usa, Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.